Arabic Arabic English English French French German German
dark

FDA Approves Updated ADUHELM™ Prescribing Information to Emphasize Population Studied in Clinical TrialsADUHELM should be initiated in patients with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s dementia

Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced the U.S. Food and Drug Administration (FDA) has approved an updated label for ADUHELM™ (aducanumab-avwa) injection 100 mg/mL solution. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Treadmill exercise alleviates neuronal damage by suppressing NLRP3 inflammasome and microglial activation.

Next Post

BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC)

Related Posts
Total
0
Share